SCHEMBL3011003

SCHEMBL3011003

Cc1cc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
ALDH1A1 P00352 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NPSR1 Q6W5P4 4/20 0.45
HTT P42858 4/20 0.45
LMNA P02545 3/20 0.45
USP2 O75604 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 4/20 0.44
PKM P14618 1/20 0.43
MAPT P10636 3/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 2/20 0.42
RECQL P46063 1/20 0.42
GBA1 P04062 1/20 0.41
HSD11B1 P28845 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013533 0.93 SMN1; SMN2 (0.47) POLBSMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL3010162 0.91 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1L3MBTL1HTTUSP2
SCHEMBL3017281 0.91 ALDH1A1 (0.39) POLBSMN1; SMN2ALDH1A1L3MBTL1NPSR1
SCHEMBL3006756 0.91 MAPT (0.46) POLBSMN1; SMN2ALDH1A1L3MBTL1NPSR1
SCHEMBL3013468 0.91 HTT (0.45) POLBSMN1; SMN2ALDH1A1L3MBTL1NPSR1
SCHEMBL3010553 0.90 SMN1; SMN2 (0.46) POLBSMN1; SMN2ALDH1A1L3MBTL1LMNA
SCHEMBL3007181 0.90 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1L3MBTL1HTTLMNA
SCHEMBL3015347 0.89 LMNA (0.45) POLBSMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL3015126 0.89 POLB (0.47) POLBSMN1; SMN2ALDH1A1L3MBTL1NPSR1
SCHEMBL3019344 0.88 SMN1; SMN2 (0.44) POLBSMN1; SMN2ALDH1A1L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.